1,298
Views
12
CrossRef citations to date
0
Altmetric
Gene of the Issue

TBXA2R gene variants associated with bleeding

&
Pages 739-742 | Received 30 Apr 2018, Accepted 01 Jun 2018, Published online: 08 Aug 2018

References

  • Hirata M, Hayashi Y, Ushikubi F, Yokota Y, Kageyama R, Nakanishi S, Narumiya S. Cloning and expression of cDNA for a human thromboxane A2 receptor. Nature. 1991;349:617–620. doi:10.1038/349617a0.
  • Kamae T, Kiyomizu K, Nakazawa T, Tadokoro S, Kashiwagi H, Honda S, Kanakura Y, Tomiyama Y. Bleeding tendency and impaired platelet function in a patient carrying a heterozygous mutation in the thromboxane A2 receptor. J Thrombosis Haemostasis: JTH. 2011;9:1040–1048. doi:10.1111/j.1538-7836.2011.04245.x.
  • Ting HJ, Murad JP, Espinosa EV, Khasawneh FT. Thromboxane A2 receptor: biology and function of a peculiar receptor that remains resistant for therapeutic targeting. J Cardiovasc Pharmacol Ther. 2012;17:248–259. doi:10.1177/1074248411424145.
  • Bousser MG, Amarenco P, Chamorro A, Fisher M, Ford I, Fox KM, Hennerici MG, Mattle HP, Rothwell PM, de Cordoue A, et al. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. Lancet. 2011;377:2013–2022. doi:10.1016/S0140-6736(11)60600-4.
  • Nurden AT, Pillois X. ITGA2B and ITGB3 gene mutations associated with Glanzmann thrombasthenia. Platelets. 2018;29:98–101. doi:10.1080/09537104.2017.1371291.
  • Mumford AD, Dawood BB, Daly ME, Murden SL, Williams MD, Protty MB, Spalton JC, Wheatley M, Mundell SJ, Watson SP. A novel thromboxane A2 receptor D304N variant that abrogates ligand binding in a patient with a bleeding diathesis. Blood. 2010;115:363–369. blood-2009-08-236976 [pii] doi:10.1182/blood-2009-08-236976.
  • Mumford AD, Nisar S, Darnige L, Jones ML, Bachelot-Loza C, Gandrille S, Zinzindohoue F, Fischer AM, Mundell SJ, Gaussem P, et al. Platelet dysfunction associated with the novel Trp29Cys thromboxane A(2) receptor variant. J Thrombosis Haemostasis: JTH. 2013;11:547–554. doi:10.1111/jth.12117.
  • Nisar SP, Lordkipanidze M, Jones ML, Dawood B, Murden S, Cunningham MR, Mumford AD, Wilde JT, Watson SP, Mundell SJ, et al. A novel thromboxane A2 receptor N42S variant results in reduced surface expression and platelet dysfunction. Thromb Haemost. 2014;111. doi:10.1160/TH13-08-0672.
  • Hirata T, Kakizuka A, Ushikubi F, Fuse I, Okuma M, Narumiya S. Arg60 to Leu mutation of the human thromboxane A2 receptor in a dominantly inherited bleeding disorder. J Clin Invest. 1994;94:1662–1667. doi:10.1172/JCI117510.
  • Fuse I, Hattori A, Mito M, Higuchi W, Yahata K, Shibata A, Aizawa Y. Pathogenetic analysis of five cases with a platelet disorder characterized by the absence of thromboxane A2 (TXA2)-induced platelet aggregation in spite of normal TXA2 binding activity. Thromb Haemost. 1996;76:1080–1085.
  • Chakraborty R, Pydi SP, Gleim S, Bhullar RP, Hwa J, Dakshinamurti S, Chelikani P. New insights into structural determinants for prostanoid thromboxane A2 receptor- and prostacyclin receptor-G protein coupling. Mol Cell Biol. 2013;33:184–193. doi:10.1128/MCB.00725-12.
  • Capra V, Veltri A, Foglia C, Crimaldi L, Habib A, Parenti M, Rovati GE. Mutational analysis of the highly conserved ERY motif of the thromboxane A2 receptor: alternative role in G protein-coupled receptor signaling. Mol Pharmacol. 2004;66:880–889. doi:10.1124/mol.104.001487.
  • Nisar SP, Jones ML, Cunningham MR, Mumford AD, Mundell SJ, Group UGS. Rare platelet GPCR variants: what can we learn? Br J Pharmacol. 2015;172:3242–3253. doi:10.1111/bph.12941.
  • Norman JE, Cunningham MR, Jones ML, Walker ME, Westbury SK, Sessions RB, Mundell SJ, Mumford AD. Protease-activated receptor 4 variant p.Tyr157Cys reduces platelet functional responses and alters receptor trafficking. Arterioscler Thromb Vasc Biol. 2016;36:952–960. doi:10.1161/ATVBAHA.115.307102.
  • Rosenbaum DM, Rasmussen SG, Kobilka BK. The structure and function of G-protein-coupled receptors. Nature. 2009;459:356–363. doi:10.1038/nature08144.
  • Mundell SJ, Rabbolini D, Gabrielli S, Chen Q, Aungraheeta R, Hutchinson JL, Kilo T, Mackay J, Ward CM, Stevenson W, et al. Receptor homodimerization plays a critical role in a novel dominant negative P2RY12 variant identified in a family with severe bleeding. J Thrombosis Haemostasis: JTH. 2018;16:44–53. doi:10.1111/jth.13900.
  • Capra V, Mauri M, Guzzi F, Busnelli M, Accomazzo MR, Gaussem P, Nisar SP, Mundell SJ, Parenti M, Rovati GE. Impaired thromboxane receptor dimerization reduces signaling efficiency: a potential mechanism for reduced platelet function in vivo. Biochem Pharmacol. 2017;124:43–56. doi:10.1016/j.bcp.2016.11.010.
  • Gleim S, Stitham J, Tang WH, Li H, Douville K, Chelikani P, Rade JJ, Martin KA, Hwa J. Human thromboxane A2 receptor genetic variants: in silico, in vitro and “in platelet” analysis. PloS One. 2013;8:e67314. doi:10.1371/journal.pone.0067314.
  • Jones ML, Norman JE, Morgan NV, Mundell SJ, Lordkipanidze M, Lowe GC, Daly ME, Simpson MA, Drake S, Watson SP, et al., group UGs. Diversity and impact of rare variants in genes encoding the platelet G protein-coupled receptors. Thromb Haemost. 2015;113:826–837. doi:10.1160/TH14-08-0679.
  • Bastida JM, Lozano ML, Benito R, Janusz K, Palma-Barqueros V, Del Rey M, Hernandez-Sanchez JM, Riesco S, Bermejo N, Gonzalez-Garcia H, et al. Introducing high-throughput sequencing into mainstream genetic diagnosis practice in inherited platelet disorders. Haematologica. 2018;103:148–162. doi:10.3324/haematol.2017.171132.
  • Maclachlan A, Watson SP, Morgan NV. Inherited platelet disorders: insight from platelet genomics using next-generation sequencing. Platelets. 2017;28:14–19. doi:10.1080/09537104.2016.1195492.